1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Analysis of Alnylam Pharmaceuticals

Analysis of Alnylam Pharmaceuticals

  • March 2015
  • -
  • Aruvian's R'search
  • -
  • 120 pages

Based in the United States, biopharmaceutical company Alnylam Pharmaceuticals is developing therapies on the foundation of ribonucleic acid interface (RNAi). The company wants to use the ribonucleic acid interface (RNAi) for the treatment of genetically defined diseases.

Aruvian’s R’search presents Analysis of Alnylam Pharmaceuticals. A complete and comprehensive analysis of Alnylam Pharmaceuticals, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.

Company analysis from Aruvians includes a history of Alnylam Pharmaceuticals, a business segment analysis of the segments Alnylam Pharmaceuticals operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.

A financial analysis of Alnylam Pharmaceuticals is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.

A SWOT Framework Analysis of Alnylam Pharmaceuticals completes this in-depth company analysis.

Table Of Contents

Analysis of Alnylam Pharmaceuticals
A. Executive Summary

B. Looking at the Industry
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective

C. Industry PEST Framework Analysis
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects

D. Looking at Alnylam Pharmaceuticals
D.1 Company Profile
D.2 History of the Company
D.3 Ownership Pattern in the Company
D.3.1 Major Holders
D.3.2 Major Direct Holders
D.3.3 Top Institutional Holders
D.3.4 Top Mutual Fund Holders
D.4 Organizational Divisions
D.5 Profiling the Key Executives
D.6 Products and Services

E. Looking at Business
E.1 Business Segments
E.2 Geographical Segments
E.3 Company Subsidiaries

F. SWOT Framework Analysis
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome

G. Profiling the Competition
G.1 Marina Biotech, Inc.
G.1.1 Corporate Profile
G.1.2 Business Segments Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Tekmira Pharmaceuticals Corporation
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Valeant Pharmaceuticals International, Inc.
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis

H. Financial Analysis of Alnylam Pharmaceuticals
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit and Loss Statement
H.4 Ratio Analysis
H.4.1 Capital Market Ratios
H.4.2 Annual Ratios
H.4.3 Quarterly Ratios

I. Future Perspective

J. Glossary of Terms

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.